Clinical Trials Logo

Burkholderia Infections clinical trials

View clinical trials related to Burkholderia Infections.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT02453789 Completed - Cystic Fibrosis Clinical Trials

A Study of OligoG in Cystic Fibrosis Subjects With Burkholderia Spp. Infection

SMR-2591
Start date: February 2015
Phase: Phase 2
Study type: Interventional

The purpose of the study is to assess the efficacy of Alginate oligosaccharide (OligoG) dry powder for inhalation in cystic fibrosis (CF) patients with a Burkholderia spp. infection.

NCT ID: NCT02212587 Completed - Cystic Fibrosis Clinical Trials

Tobramycin Inhalation Powder (TIP) in Cystic Fibrosis Patients Infected With Burkholderia Cepacia Complex

Start date: September 2014
Phase: Phase 1
Study type: Interventional

The objective of this study is to determine if tobramycin inhalation powder (TIP) can reduce the amount of Burkholderia Cepacia Complex (BCC) species - type of bacteria, in the sputum of cystic fibrosis patient.

NCT ID: NCT01059565 Completed - Cystic Fibrosis Clinical Trials

Safety and Efficacy Study of Aztreonam for Inhalation Solution (AZLI) in Patients With Cystic Fibrosis and Chronic Burkholderia Species Infection

Start date: February 2010
Phase: Phase 3
Study type: Interventional

The purpose of this research study was to determine if an experimental drug called Aztreonam for Inhalation Solution (AZLI) was safe and effective to treat Burkholderia lung infections in patients with cystic fibrosis (CF). Spirometry was used to assess pulmonary function, and the revised Cystic Fibrosis Questionnaire (CFQ-R) was used to assess quality of life. The CFQ-R is a validated, patient-reported outcome tool used to measure health-related quality of life for children and adults with CF. The study consisted of a 24-week randomized phase, and a 24-week open-label phase. Primary and secondary efficacy analyses were conducted for the 24-week randomized phase only. Safety data were collected for both the randomized and open-label phases.